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www.cdatm.orgAbstractObjective: To systematically evaluate the prognosis in patients with breast cancer with ipsilateral supraclavicular lymph node
metastasis (SLNM) versus patients with stage IIIb/c or IV breast cancer, so as to provide evidence for clinical practice and research.
Methods: Computer retrieval from PubMed, Cochrane Libratory, CNKI (China National Knowledge Infrastructure), CBM and
Wanfang Database with the assistance of other retrieval tools. All the studies evaluating the prognosis in patients with breast cancer
with ipsilateral supraclavicular lymph node metastasis versus patients with stage IIIb/c or IV breast cancer were collected. Quality
assessment was performed for the included data based on the quality assessment criteria appropriate for this study. Meta-analysis
was performed using RevMan 5.3 software.
Results: A total of four references (1277 patients) were included. Assessment of influences on prognosis: As compared to the stage
IIIb/c group, the 5-year survival rate was slightly lower in the SLNM group (relative risk (RR) 0.79; 95% confidence interval (CI)
0.59e1.06; Z ¼ 1.55, P ¼ 0.12), but there was no statistical significance; in contrast, the 5-year survival rate was significantly
increased in the SLNM group as compared to the stage IV group (RR ¼ 2.70; 95%CI: 1.36e5.37; Z ¼ 2.84, P ¼ 0.005). As
compared to the stage IIIb/c group, the 5-year disease-free survival rate was lower in the SLNM group (RR ¼ 0.65; 95%CI:
0.40e1.05; Z ¼ 1.75, P ¼ 0.08); however, there was no statistical significance.
Conclusions: In patients with advanced breast cancer receiving combined therapy, the prognosis in patients with breast cancer
with ipsilateral SLNM was significantly better than in those with stage IV breast cancer, and slightly worse than those with stage
IIIb/c breast cancer. However, with the scarcity and poor quality of these observational studies, the long-term prognosis remains to
be further verified in large-sample, high-quality studies.
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an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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237X.-H. Liu et al. / Chronic Diseases and Translational Medicine 1 (2015) 236e242The incidence of breast cancer with ipsilateral
supraclavicular lymph node metastasis (SLNM)
without distant metastasis is as low as 1e4%.1 In the
5th edition of the AJCC-TNM breast cancer staging
system, the stage assigned to breast cancer with SLNM
was modified from N3 to M1, possibly because ipsi-
lateral SLNM in breast cancer is typically a sign of a
poor prognosis as the majority of the patients would
develop distant metastasis within one year.2e4 In the
early 21st century, Brito et al5 reported for the first
time a significantly better prognosis in patients with
breast cancer with ipsilateral SLNM than in those with
distant metastasis after receiving combined therapy
including surgery, radiotherapy and chemotherapy. In
the 6th edition of the AJCC-TNM breast cancer staging
system, breast cancer with ipsilateral SLNM, which
was no longer regarded as distant metastasis, was re-
classified as stage IIIc instead of stage IV.6,7 Never-
theless, such a staging has not been adequately evi-
denced, and no consensus has yet been reached on the
selection of the treatment regimen for breast cancer
with ipsilateral SLNM. Through meta-analysis of the
literature on breast cancer with ipsilateral SLNM, this
study was intended to explore its clinical relevance, in
an attempt to provide references for further clinical
practice and research.
Methods
Our meta-analysis was conducted in accordance
with the ‘Preferred Reporting Items for Systematic
Reviews and Meta-analysis’ (PRISMA) guidelines.8
Reference search strategies
Computer retrieval for the references published
from 1 January, 2000 to 21 December, 2015 was per-
formed from Pubmed, Cochrane Library, CNKI (China
National Knowledge Infrastructure), CBM and Wan-
fang Data. All the studies comparing the prognosis in
patients with breast cancer with ipsilateral SLNM vs.
stage IIIb/c or IV breast cancer were collected by
manual tracing or internet searching at Google Aca-
demics. Search items including Medical Subject
Headings (MeSH) words and text words were related
to breast cancer, ipsilateral supraclavicular lymph node
metastasis, outcome and prognosis. References pub-
lished during the years 2000e2015 and written simply
in English were to be collected. To indentify more
studies, we manually searched the reference lists of
selected articles or review articles. We also contacted
authors for additional data if necessary.Inclusion criteria
Studies that satisfied the following criteria were
included in this meta-analysis: 1) prospective or
retrospective studies with the follow-up duration more
than five years; 2) breast cancer patients with ipsilat-
eral SLNM without distant metastasis and patients with
stage IIIb/c or IV breast cancer as evidenced by im-
aging or pathological diagnosis; 3) reference must
provide 5-year overall survival (OS) rate or 5-year
disease-free survival (DFS) rate between two groups;
4) reference must have a sample size of at least 30
patients in each group. References published on the
same population were to be reduced so that only the
study with the best quality or the largest sample size
was to be included in the study.
Data extraction
The references were selected by two reviewers (Xu-
Hong Liu, Lei Zhang) independently according to the
pre-defined inclusion criteria. Discrepancies were
resolved through discussion with Bo Chen. The
following data were extracted in each study, including
the first author's name, the year of publication, country,
the follow-up duration, method of outcome assessment,
the diagnosis measurement of breast cancer, whether
combined therapy was used or not, and the sample size.
Reference quality assessment
Our meta-analysis used the NewcastleeOttawa
Quality Assessment Scale (NOS) to evaluate the
quality of each included study.9 The studies were
assessed in three areas: the selection of exposed and
unexposed participants; the comparability of the
groups; and the assessment of the outcome. Total
scores of each study range from one to nine; with nine
being the maximum and 7 scores was considered
high quality.
Statistical analyses
An I2 test was used for evaluating heterogenicity
between different studies' results. When statistical
homogenicity was found between different studies
(I2 < 50%), a fixed-effect model was used for analysis;
a random-effect model was used when statistical het-
erogenicity was found between different studies
(I2  50%).10 Potential publication bias was evaluated
by a funnel plot. All analyses were performed with
RevMan 5.3 software.
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Reference retrieval results
Preliminary retrieval identified 311 relevant refer-
ences, of which 98 were excluded by Endnote Soft-
ware due to redundancy and 169 were excluded by
reviewing the title and abstract, leaving 44 prelimi-
narily included. Among them 40/44 were excluded
after reviewing the body text, leaving four references
finally included that reported a total of 1277 patients
(Fig. 1).
General characteristics and methodology evaluation
of the included studies
The four studies finally included are comparable; as
none of them report statistically significant differences
between the two groups in clinical stage, treatment
approach, or follow-up duration, etc., suggesting gen-
eral consistency between groups. The general charac-
teristics of the included references are presented in
Table 1, and the methodology quality assessment is
presented in Table 2.
Results of meta-analysis
Five-year overall survival rate (SLNM vs IIIb/c) As
heterogenicity was not shown between the four refer-
ences included (c2 ¼ 9.12, P ¼ 0.03, I2 ¼ 67%), a
random-effect model was used. As compared to the
stage IIIb/c group, the 5-year survival rate was lower in
the SLNM group (relative risk (RR) ¼ 0.79; 95%
confidence interval (CI): 0.59e1.06; Z ¼ 1.55,
P ¼ 0.12) (Fig. 2).Fig. 1. Flow diagram of reference selection procedures.Five-year overall survival rate (SLNM vs. IV) As
heterogenicity was shown between two included ref-
erences (c2 ¼ 2.87, P ¼ 0.09, I2 ¼ 65%), a random-
effect model was used. The 5-year survival rate
significantly increased in the SLNM group as
compared to the stage IV group (RR ¼ 2.70; 95%CI:
1.36e5.37; Z ¼ 2.84, P ¼ 0.005), as illustrated in
Fig. 3.
Five-year disease-free survival rate (SLNM vs. IIIb/
c) As heterogenicity was shown between three refer-
ences included (c2 ¼ 7.60, P ¼ 0.02, I2 ¼ 74%), a
random-effect model was used. As compared to the
stage IIIb/c group, the 5-year disease-free survival rate
was significantly lower (RR ¼ 0.65; 95%CI:
0.40e1.05; Z ¼ 1.75, P ¼ 0.08), as illustrated in Fig. 4.
Publication bias
In this study, a funnel plot was used to analyze the
two outcome variables (5-year overall survival rate and
5-year disease-free survival rate). As a result, asym-
metry was shown in the funnel plot for the influences
on 5-year overall survival rate, indicating a potential
publication bias (Fig.5, Fig.6). However, the funnel
plot for the influences on 5-year disease-free survival
rate indicates a low potential for a publication bias
(Fig.7).
Discussion
Results of this Meta analysis suggest that, after
combined therapy, both the 5-year survival rate and 5-
year disease-free survival rate were lower in breast
cancer patients with ipsilateral SLNM without distant
metastasis than in those with stage IIIb/c breast cancer;
although the outcome showed no statistical signifi-
cance, the trend of the data was on the decline. In
contrast, the 5-year survival rate was significantly
higher than in those with stage IV breast cancer and the
difference was statistically significant. A random-effect
model was used for analysis of the prognostic in-
dicators in this meta-analysis because of the hetero-
genicity between the studies included. The
methodology assessment of reference quality suggests
that the references tend to have intermediate or low
quality, which might be primarily attributable to the
difficulty in blinding the treatment regimens. Other
limitations of this study mainly lie in that they are
lacking in analysis of the results of the long-term
prognosis and outcome indicators; some of the studies
have an overly small sample size; and that the funnel
plot indicates a certain publication bias in this study.
Table 2
Quality assessment of included references.
Author Year Selection Comparability Outcome Score
Chen et al11 2006 ++++ + ++ 7
Ogino et al12 2011 +++ + +++ 7
Dellapasqua
et al13
2014 ++++ ++ ++ 8
Noh et al14 2015 +++ ++ ++ 7
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239X.-H. Liu et al. / Chronic Diseases and Translational Medicine 1 (2015) 236e242Brito et al5 initially proposed that the patients with
ipsilateral SLNM would present with a prognosis that
is more similar to that of patients with locally
advanced breast cancer than of the patients with distant
metastasis. Subsequently Chen,11 Huang,15 Fan,16
Park,17 Ogino,12 Dellapasqua13 and Noh14 all succes-
sively reached similar conclusions. The rationality of
classifying breast cancer with ipsilateral SLNM as
stage N3c instead of M1 in the 6th edition of AJCC-
TNM breast cancer staging system was evaluated by
the treatment status in these patients. Meanwhile, re-
sults of this meta-analysis suggest a significantly
different prognosis in breast cancer patients with ipsi-
lateral SLNM from stage M1 patients and a similar
prognosis to stage N3c patients. However, though the
results of comparing to the stage N3c group were no
statistically significant (a possible reason is the small
sample size), we could see the differences in the data
with a slightly lower 5-year OS and DFS. Therefore,
the treatment regimen for breast cancer patients with
ipsilateral SLNM should be different from those for
stage N3c and stage M1. Chen et al11 argue that good
cervical lymph node dissection or other cervical con-
trols, including chemotherapy, could result in signifi-
cantly improved patient prognosis and survival; this
however remains to be confirmed by large-sample,
multi-center studies.
Conclusion
In conclusion, this study suggests that the prognosis
for breast cancer patients with ipsilateral SLNM is
similar to patients with stages IIIb/c disease and
different from patients with stage IV disease. The 5-
year OS and DFS of the breast cancer patients with
ipsilateral SLNM is slightly lower compared with that
of the stage IIIb/c group, and radical, instead of
palliative therapy, seems more plausible for these pa-
tients. In addition, vigilance should be exercised for the
high risk of distant metastasis in these patients,
requiring a combined therapeutic approach including
radical surgery, radiotherapy and chemotherapy, and
Fig. 2. Meta analysis results of 5-year survival rate in SLNM group vs. stage IIIb/c breast cancer group.
Fig. 3. Meta analysis results of 5-year survival rate in SLNM group vs. stage IV breast cancer group.
Fig. 4. Meta analysis results of 5-year disease-free survival rate in SLNM group vs. stage IIIb/c breast cancer group.
Fig. 5. Funnel plot for 5-year survival rate in SLNM group vs. stage IIIb/c breast cancer group.
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Fig. 6. Funnel plot for 5-year survival rate in SLNM group vs. stage IV breast cancer group.
Fig. 7. Funnel plot for 5-year disease-free survival rate in SLNM group vs. stage IIIb/c breast cancer group.
241X.-H. Liu et al. / Chronic Diseases and Translational Medicine 1 (2015) 236e242endocrine therapy, etc. In order to further promote the
clinical application of this effective approach, large-
sample, multi-center studies with high quality are
necessary to improve the evidential robustness of these
observations.
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